There was a significant difference in progression-free survival and overall survival between the acid suppressed and no acid suppression groups. Further research is required to confirm this potential interaction.
Background: Sunitinib, a tyrosine kinase inhibitor (TKI), is standard therapy in metastatic RCC (mRCC). Developing side effects may be a marker of sufficient treatment doses. But as an oral drug, a potential issue is pH-dependent absorption. Recent evidence suggests TKI plasma levels can be altered by concomitant use of acid suppression therapy. Given gastroesophageal reflux disease (GERD) is a side effect of sunitinib and has high prevalence, this study aims to determine if coadministration of acid suppression therapy and sunitinib affected clinical outcomes in mRCC. Methods: mRCC patients treated with sunitinib between two cancer centres from 2007 to 2013 were retrospectively reviewed. Patients were excluded if they received ≤ 1 week of treatment. Aside from demographics and histologic subtype, Memorial Sloan Kettering Cancer Center (MSKCC) and Heng prognostic scores were calculated. Sunitinib dose reductions were noted to divide patients into those that received 50 mg, 37.5 mg, or 25 mg. Patients were identified as receiving acid suppression if their pharmacy records included a proton pump inhibitor (PPI). Patients were considered taking these medications concomitantly if dates for PPI overlapped their sunitinib prescription by ≥ 20% of treatment duration. Progression free survival (PFS) and overall survival (OS) were primary endpoints. Results: Of 383 mRCC patients identified, 379 were eligible for review. Median age was 62.7 years, 276 male, and 103 female. 286 had clear-cell histology and 93 non-clear cell. 47 patients were identified as continuously taking concomitant PPI, 146 intermittently, and 186 none at all. Median PFS for continuous, intermittent and no-PPI therapy groups were 4.3 months, 15.0 months, and 5.4 months, respectively (p<0.0001). OS for the three groups were 9.3 months, 34.3 months, and 12.1 months, respectively (p<0.0001). In multivariate analysis considering age, gender, histologic subtype, prior nephrectomy, and Heng score, Cox proportional hazards ratios for PFS and OS between continuous and no-PPI therapy groups were 2.08 (95% CI 1.43-3.05, p=0.0002) and 2.06 (95% CI 1.37-3.11, p=0.0006), respectively. Switching Heng for MSKCC score found similar hazards ratios of 2.06 (95% CI 1.41-3.01, p= 0.0002) and 2.09 (95% CI 1.39-3.14, p=0.0004), respectively. Our study found a trend to improved PFS and OS for those requiring a dose reduction (p=0.08). Effects of PPI therapy were still significant considering dose reductions. Conclusion: This large population based study demonstrates sunitinib outcomes are affected by gastric acidity. Results lend further support that PPI therapy can alter TKI absorption; particularly as the intermittent PPI therapy group performed best suggesting that these patients were likely placed on PPI due to sunitinib toxicity. Consequently, they were effectively dose reduced using PPIs rather than decreasing administration dosage. Citation Format: Michael P. Chu, Vincent Ha, Margaret Ngo, Sunita Ghosh, Carole R. Chambers, Michael B. Sawyer. Acid suppression therapy impairs sunitinib efficacy in renal cell cancer (RCC). [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4628. doi:10.1158/1538-7445.AM2014-4628
The impact of gastric acid suppression therapy on tyrosine kinase inhibitors in advanced cancer patients Background Oral tyrosine kinase inhibitors (TKIs) are used across tumor subtypes. Oral drug absorption is dependent on numerous factors including gastric acidity. Few studies have examined effects of gastric acid suppressants such as proton pump inhibitors (PPIs) on TKI outcomes. This study aims to determine if concurrent PPIs and TKIs impair progression free (PFS) and overall survival (OS) in patients (pts). Methods Advanced/metastatic non-small cell lung cancer (NSCLC) patients receiving erlotinib from 2007 to 2012 and renal cell cancer (RCC) patients receiving sunitinib from 2007 to 2013 were retrospectively reviewed. The review included the Alberta outpatient/retail pharmacy databases. Pts with ≤ 1 week of therapy were excluded. Aside from demographics, pts were identified as concurrently receiving acid suppression if their pharmacy records included a PPI with prescription dates that overlapped by ≥ 20% of TKI treatment duration. PFS and OS were primary endpoints.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.